Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 79
- Registration Number
- NCT05662319
- Locations
- 🇺🇸
Center for Inherited Blood Disorders (CIBD) Site Number : 8400012, Orange, California, United States
🇺🇸University of California San Diego Site Number : 8400011, San Diego, California, United States
🇺🇸University of Minnesota Site Number : 8400016, Minneapolis, Minnesota, United States
A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
- Conditions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 148
- Registration Number
- NCT05649813
- Locations
- 🇰🇼
Investigational Site Number: 01, Kuwait, Kuwait
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 174
- Registration Number
- NCT05630547
- Locations
- 🇧🇪
Investigational Site Number : 0560001, Bruxelles, Belgium
🇧🇬Investigational Site Number : 1000002, Sofia, Bulgaria
🇨🇦Investigational Site Number : 1240002, Ottawa, Ontario, Canada
A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
- Conditions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 47885
- Registration Number
- NCT05628090
- Locations
- 🇫🇷
Investigational Site Number :, Chilly-Mazarin, France
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT05624112
- Locations
- 🇨🇳
Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital), Guangzhou, Guangdong, China
A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21
- Registration Number
- NCT05607173
- Locations
- 🇧🇬
Investigational Site Number: 100-0001, Sofia, Bulgaria
🇫🇷Investigational site 250-0001, Rennes, France
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
- Conditions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 82
- Registration Number
- NCT05607160
- Locations
- 🇩🇪
Investigational site, Germany, Germany
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 182
- Registration Number
- NCT05588843
- Locations
- 🇺🇸
Om Research LLC- Site Number : 8400014, Lancaster, California, United States
🇺🇸BVL Research- Site Number : 8400015, Liberty, Missouri, United States
🇺🇸Gastro One - Germantown- Site Number : 8400002, Germantown, Tennessee, United States
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 285
- Registration Number
- NCT05584670
- Locations
- 🇳🇱
Erasmus MC_Investigational Site Number : 5280003, Rotterdam, Netherlands
🇮🇱Sheba Medical Center - PPDS_Investigational Site Number : 3760003, Ramat Gan, Israel
🇺🇸John Theurer Cancer Center Site Number : 8400001, Hackensack, New Jersey, United States
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 62
- Registration Number
- NCT05552859
- Locations
- 🇺🇸
Agile Clinical Research Trials, LLC Site Number: 8400001, Atlanta, Georgia, United States
🇺🇸Emory University Site Number: 8400032, Atlanta, Georgia, United States
🇺🇸Advanced Medical Research Site Number: 8400012, Maumee, Ohio, United States